[go: up one dir, main page]

WO2012001196A3 - Vectores alfavirales y usos de los mismos para la expresión de genes heterólogos - Google Patents

Vectores alfavirales y usos de los mismos para la expresión de genes heterólogos Download PDF

Info

Publication number
WO2012001196A3
WO2012001196A3 PCT/ES2011/070462 ES2011070462W WO2012001196A3 WO 2012001196 A3 WO2012001196 A3 WO 2012001196A3 ES 2011070462 W ES2011070462 W ES 2011070462W WO 2012001196 A3 WO2012001196 A3 WO 2012001196A3
Authority
WO
WIPO (PCT)
Prior art keywords
forming functional
virions
nuclecapsids
propagative
expression vectors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/ES2011/070462
Other languages
English (en)
French (fr)
Other versions
WO2012001196A2 (es
Inventor
Alejandro Mario Aranda
Jaione Bezunartea Bezunartea
Jesús María PRIETO VALTUEÑA
José Ignacio QUETGLAS MAS
Marta RUIZ GUILLÉN
Cristian Smerdou Picazo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proyecto de Biomedicina CIMA SL
Original Assignee
Proyecto de Biomedicina CIMA SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto de Biomedicina CIMA SL filed Critical Proyecto de Biomedicina CIMA SL
Publication of WO2012001196A2 publication Critical patent/WO2012001196A2/es
Publication of WO2012001196A3 publication Critical patent/WO2012001196A3/es
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se relaciona con un vector basado en un replicón alfaviral en el que la secuencia que codifica la poliproteína estructural se ha modificado mediante una deleción en la región que codifica la proteína de la cápsida de forma que dicha secuencia no es capaz de producir una proteína de la cápsida capaz de formar nucleocápsidas funcionales. Estos vectores son capaces de propagarse a células vecinas de forma dependiente de las proteínas de la espícula por lo que son adecuados para la expresión de genes heterólogos en una célula u organismo de interés. La invención se relaciona también con viriones que comprenden el vector de la invención así como con métodos para la generación de dichos viriones y con el uso del vector y de los viriones para expresar proteínas heterólogas en una célula de interés y para terapia.
PCT/ES2011/070462 2010-06-28 2011-06-27 Vectores alfavirales y usos de los mismos para la expresión de genes heterólogos Ceased WO2012001196A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ESP201030998 2010-06-28
ES201030998 2010-06-28

Publications (2)

Publication Number Publication Date
WO2012001196A2 WO2012001196A2 (es) 2012-01-05
WO2012001196A3 true WO2012001196A3 (es) 2012-02-23

Family

ID=44677910

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2011/070462 Ceased WO2012001196A2 (es) 2010-06-28 2011-06-27 Vectores alfavirales y usos de los mismos para la expresión de genes heterólogos

Country Status (1)

Country Link
WO (1) WO2012001196A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2523016B1 (es) 2013-05-20 2015-09-09 3P Biopharmaceuticals Vectores alfavirales y líneas celulares para la producción de proteínas recombinantes
CN105176936B (zh) * 2015-10-23 2019-01-11 中国科学院武汉物理与数学研究所 复制耐受型的西门利克森林病毒的亚克隆及制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004085660A2 (en) * 2003-03-20 2004-10-07 Alphavax, Inc. Improved alphavirus replicons and helper constructs
WO2007102140A2 (en) * 2006-03-08 2007-09-13 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin A semliki forest virus replication competent vector with enhanced biosafety
WO2011064437A2 (es) * 2009-11-26 2011-06-03 Proyecto De Biomedicina Cima, S.L. Vectores virales y procedimientos útiles en la preparación de gdnf

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2057377C1 (ru) 1993-08-23 1996-03-27 Уральский электрохимический комбинат Способ переработки оружейного высокообогащенного урана и его сплавов в топливный материал для атомных реакторов
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
GB9326271D0 (en) 1993-12-23 1994-02-23 Zeneca Ltd Expression of self-processing polyprotein in transgenic plants
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
DE10148294C1 (de) 2001-09-29 2003-01-16 Unicor Rohrsysteme Gmbh Formbackenhälfte für einen Corrugator zum Herstellen von Querrippenrohren
FI20020375A7 (fi) 2002-02-27 2003-08-28 Wahlfors Menetelmä viruksen kaltaisten partikkeleiden (VKP) tuottamiseksi, plasmidikonstrukti sekä menetelmän käytöt
EP1534737A4 (en) 2002-04-29 2007-10-31 Univ Saint Louis PEPTIDANTAGONISTS OF MEMBERS OF THE TGF BETA FAMILY AND THEIR THERAPEUTIC APPLICATION
BR122019005271B1 (pt) 2002-12-13 2020-10-13 Alphavax, Inc. método para a preparação de partículas de replicon de alfavírus (arps)
ES2304069B1 (es) 2003-08-22 2009-08-12 Proyecto De Biomedicina Cima, S.L. Peptidos con capacidad de unirse al factor transformante de crecimiento beta 1 (tgf-b1).
WO2006135436A2 (en) 2004-10-22 2006-12-21 University Of Florida Research Foundation, Inc. Inhibition of gene expression and therapeutic uses thereof
KR101281208B1 (ko) 2005-05-11 2013-07-26 필로겐 에스.피.에이. 피브로넥틴 ｅｄ-ｂ에 대한 항체 ｌ１９ 및 인터루킨１２의 융합 단백질

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004085660A2 (en) * 2003-03-20 2004-10-07 Alphavax, Inc. Improved alphavirus replicons and helper constructs
WO2007102140A2 (en) * 2006-03-08 2007-09-13 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin A semliki forest virus replication competent vector with enhanced biosafety
WO2011064437A2 (es) * 2009-11-26 2011-06-03 Proyecto De Biomedicina Cima, S.L. Vectores virales y procedimientos útiles en la preparación de gdnf

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
C P CHIKKANNA-GOWDA ET AL: "Regression of mouse tumours and inhibition of metastases following administration of a Semliki Forest virus vector with enhanced expression of IL-12", GENE THERAPY, vol. 12, no. 16, 1 August 2005 (2005-08-01), pages 1253 - 1263, XP055014072, ISSN: 0969-7128, DOI: 10.1038/sj.gt.3302561 *
CHIKKANNA-GOWDA CP, MCNALLY S, SHEAHAN BJ, FLEETON MN, ATKINS GJ.: "Inhibition of murine K-BALB and CT26 tumour growth using a Semliki Forest virus vector with enhanced expression of IL-18.", ONCOL REP., vol. 16, no. 4, October 2006 (2006-10-01), pages 713 - 719, XP002665450 *
EHRENGRUBER MARKUS U ET AL: "UNIT 4.22 Alphaviruses: Semliki Forest Virus and Sindbis Virus Vectors for Gene Transfer into Neurons", CURRENT PROTOCOLS IN NEUROSCIENCE, JOHN WILEY & SONS, INC, US, vol. suppl. 41, 1 October 2007 (2007-10-01), pages 4/22/1 - 4/22/24, XP009148022, ISSN: 1934-8576, [retrieved on 20071001], DOI: 10.1002/0471142301.NS0422S41 *
ERKUDEN CASALES ET AL: "A novel system for the production of high levels of functional human therapeutic proteins in stable cells with a Semliki Forest virus noncytopathic vector", NEW BIOTECHNOLOGY, vol. 27, no. 2, 24 February 2010 (2010-02-24), pages 138 - 148, XP055014060, ISSN: 1871-6784, DOI: 10.1016/j.nbt.2010.02.005 *
J. M. THOMAS ET AL: "Sindbis Virus Vectors Designed To Express a Foreign Protein as a Cleavable Component of the Viral Structural Polyprotein", JOURNAL OF VIROLOGY, vol. 77, no. 10, 15 May 2003 (2003-05-15), pages 5598 - 5606, XP055014427, ISSN: 0022-538X, DOI: 10.1128/JVI.77.10.5598-5606.2003 *
J. R. RODRIGUEZ-MADOZ ET AL: "Semliki Forest Virus Expressing Interleukin-12 Induces Antiviral and Antitumoral Responses in Woodchucks with Chronic Viral Hepatitis and Hepatocellular Carcinoma", JOURNAL OF VIROLOGY, vol. 83, no. 23, 1 December 2009 (2009-12-01), pages 12266 - 12278, XP055014075, ISSN: 0022-538X, DOI: 10.1128/JVI.01597-09 *
KIIVER ET AL: "Novel vectors expressing anti-apoptotic protein Bcl-2 to study cell death in Semliki Forest virus-infected cells", VIRUS RESEARCH, AMSTERDAM, NL, vol. 131, no. 1, 12 December 2007 (2007-12-12), pages 54 - 64, XP022386397, ISSN: 0168-1702, DOI: 10.1016/J.VIRUSRES.2007.08.008 *
LUNDSTROM K: "Biology and application of alphaviruses in gene therapy", GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, vol. 12, no. Suppl. 1, 1 October 2005 (2005-10-01), pages S92 - S97, XP002614743, ISSN: 0969-7128, DOI: 10.1038/SJ.GT.3302620 *
QUETGLAS J I ET AL: "Alphavirus vectors for cancer therapy", VIRUS RESEARCH, AMSTERDAM, NL, vol. 153, no. 2, 1 November 2010 (2010-11-01), pages 179 - 196, XP027367775, ISSN: 0168-1702, [retrieved on 20100806] *
SMERDOU C ET AL: "Two-helper RNA system for production of recombinant Semliki Forest virus particles", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 73, no. 2, 1 February 1999 (1999-02-01), pages 1092 - 1098, XP002139369, ISSN: 0022-538X *
STRAUSS ET AL: "The Alphaviruses: gene expression, replication, and evolution", MICROBIOLOGICAL REVIEWS, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, DC, US, vol. 58, no. 3, 1 September 1994 (1994-09-01), pages 491 - 562, XP002108834, ISSN: 0146-0749 *
ULPER ET AL: "Construction, properties, and potential application of infectious plasmids containing Semliki Forest virus full-length cDNA with an inserted intron", JOURNAL OF VIROLOGICAL METHODS, ELSEVIER BV, NL, vol. 148, no. 1-2, 3 December 2007 (2007-12-03), pages 265 - 270, XP022487620, ISSN: 0166-0934, DOI: 10.1016/J.JVIROMET.2007.10.007 *
VAHA-KOSKELA M J V ET AL: "A NOVEL NEUROTROPIC EXPRESSION VECTOR BASED ON THE AVIRULENT A7(74) STRAIN OF SEMLIKI FOREST VIRUS", JOURNAL OF NEUROVIROLOGY, INFORMA HEALTHCARE, GB, vol. 9, no. 1, 1 February 2003 (2003-02-01), pages 1 - 15, XP009016060, ISSN: 1355-0284 *
WUYANG ZHU ET AL: "Glycoprotein is enough for sindbis virus-derived DNA vector to express heterogenous genes", VIROLOGY JOURNAL, vol. 8, no. 1, 1 January 2011 (2011-01-01), pages 344 - 344, XP055013952, ISSN: 1743-422X, DOI: 10.1186/1743-422X-8-344 *

Also Published As

Publication number Publication date
WO2012001196A2 (es) 2012-01-05

Similar Documents

Publication Publication Date Title
ZA202308846B (en) Cx3cr1-binding polypeptides
MX354516B (es) Vectores que codifican el factor de viabilidad de conos derivado de bastones.
MX375379B (es) Receptores de celulas t anti - papilomavirus 16 e7 humano.
EA201492202A1 (ru) Способ экспрессии гетерологичных белков с использованием рекомбинантного вирусного вектора с минус-нитью рнк
IN2012DN00650A (es)
MX352974B (es) Moleculas de acido nucleico que codifican novedosos antigenos de herpes, vacunas que las comprenden y metodos para su uso.
MX2018010483A (es) Inmunogenos para vacunacion contra vih.
MX2014007516A (es) Procesos que utilizan vlps con capsides resistentes a hidrolasas.
DK2608806T3 (da) Epstein-barr-virusvaccine
IN2015DN02546A (es)
MX338560B (es) Enzimas de fusion que tienen actividad de n-acetilglucosaminil transferasa.
WO2016073595A8 (en) T cells and dendritic cells for polyomavirus therapy
WO2012009704A3 (en) Novel peptides and uses thereof
WO2012047679A3 (en) Consensus antigen constructs and vaccines made there form, and methods of using same to treat malaria
EA201690232A1 (ru) Генетически стабильный онколитический рнк вирус, способ его производства и применения
WO2012001196A3 (es) Vectores alfavirales y usos de los mismos para la expresión de genes heterólogos
PH12018502197A1 (en) Improved method for producing virus like particles
IN2014DN10123A (es)
ES2523016A1 (es) Vectores alfavirales y líneas celulares para la producción de proteínas recombinantes
WO2012038832A3 (en) Generation of replicating chimeric measles virus - retrovirus particles
WO2013032999A3 (en) Polydnavirus vectors
WO2011086447A3 (en) Fermentation process for the preparation of recombinant heterologous proteins
MX339728B (es) Gen sintético para expresión de schistosoma mansoni-14 en pichia pastoris, procedimientos de producción de schistosoma mansoni-14 y su uso como vacuna y medio de diagnóstico.
WO2011064437A3 (es) Vectores virales y procedimientos útiles en la preparación de gdnf
Rajasingh Reprogramming of somatic cells

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11761097

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11761097

Country of ref document: EP

Kind code of ref document: A2